Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on the company’s subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. The company is looking to investigate DMT for treatment of stroke and traumatic brain injury.
Moreau telling Proactive the committee tasked with reviewing the program has confirmed that there were no safety or tolerability issues with the highest dose, which was able to maintain plasma DMT concentrations at targeted levels and which was below the established psychedelic dose.
The company says the 2nd part of the study will include dosing subjects for 6 hours with repeated administrations over a two-week period which can be used in its first Phase 2 study for stroke and TBI.